Abstract: An anti-CD33 antibody and a preparation method therefor and an application thereof. The anti-CD33 antibody has high affinity with CD33 protein, and therefore, can be used for preparation of a drug for treating tumor and the like.

Abstract: The present invention relates to a single-domain antibody against MSLN (mesothelin) and a preparation method therefor and an application thereof. The MSLN antibody has high affinity for MSLN, and therefore can be applied to the preparation of a medicament for treating tumors, etc.

Abstract: Disclosed in the present invention are a humanized antibody that can specifically bind to TNFR2, or an antigen-binding fragment thereof. The humanized antibody or antigen-binding fragment thereof can regulate the function of immune cells and can be used in a drug for treating diseases related to immune abnormalities, such as tumours.

Abstract: An EGFR nanobody, and a preparation method therefor and the use thereof. The EGFR nanobody has high affinity for a wild-type EGRF protein, and also recognizes the EGRFvIII protein.

Abstract: CD22 antibodies, a preparation method therefor, and an application thereof. The CD22 antibodies have a high affinity to CD22 protein Therefore, the CD22 antibodies can be used in the preparation of drugs for the treatment of diseases such as tumors and autoimmune diseases.

Abstract: An antibody or antigen-binding fragment specifically binding to HER2, a multi-specific antigen binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid fragment, a vector, a host cell, a pharmaceutical composition, a kit, a preparation method, and an application thereof in treatment of tumors or cancers and detection of HER2, which is of great significance for the development of HER2 antibody therapeutic drugs and detection reagents.

Abstract: Provided are a GPC3 antibody and an application thereof, and specifically provided are an antibody or an antigen-binding fragment that specifically binds to GPC3, a multispecific antigen-binding molecule, a chimeric antigen receptor, an immune effector cell, isolated nucleic acid fragments, a vector, a host cell, a corresponding preparation method, a pharmaceutical composition, a treatment method, a pharmaceutical use, a GPC3 detection method and a detection kit. The present disclosure is of great significance in the preparation of drugs for treating cancer or tumor.

Abstract: Provided are an CD22 nano antibody, and a preparation method therefor and an application thereof. The CD22 nano antibody has high affinity with a CD22 protein, and can be used for preparing drugs for treating tumors, autoimmune diseases, etc.

Abstract: The present disclosure discloses IL-2 mutants and uses thereof. More specifically, the disclosure provides IL-2 mutants and corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the mutants or fusion proteins, IL-2 mutants or fusion proteins prepared according to the methods, pharmaceutical compositions, pharmaceutical uses, methods for treating diseases, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutants of the present disclosure have higher Tm values and improved stability; alternatively, the IL-2 mutants of the present disclosure have an increased yield or changed binding activity to the IL-2R?? complexes compared to wild-type IL-2.

Abstract: Provided are a human IL-15 molecule mutant and a fusion protein containing the IL-15 mutant and combined mutations, wherein the fusion protein can mediate the activation and amplification of immune cells and can be used for treating tumor disease

Abstract: A TIGIT antibody, an antigen-binding fragment thereof, and a medical use thereof. The present invention relates to a murine antibody, a chimeric antibody, and a humanized antibody comprising a CDR region of the TIGIT antibody, and a pharmaceutical composition comprising the TIGIT antibody and the antigen-binding fragment thereof, and a use thereof as a medicament. In particular, the present invention also relates to a use of a humanized TIGIT antibody for preparing a medicament for the treatment of TIGIT-associated diseases or conditions.

Abstract: Provided are an anti-CD73 antibody, an antigen-binding fragment thereof, and an application thereof. Specifically, provided are a murine, chimeric or humanized anti-CD73 antibody comprising a specific CDR region and an antigen-binding fragment thereof. Also provided are a pharmaceutical composition comprising the anti-CD73 antibody or the antigen-binding fragment thereof and the use thereof as a diagnostic agent and a therapeutic agent for CD73-related diseases.

Abstract: A TIM-3 antibody, an antigen-binding fragment thereof, and medical uses thereof are described. More specifically, the present invention provides a rat-derived antibody containing a CDR region of the TIM-3 antibody, a chimeric antibody or a human-derived antibody thereof, and a pharmaceutical composition containing the TIM-3 antibody and the antigen-binding fragment thereof, as well as uses thereof serving as a drug. In particular, the present invention provides uses of a human-derived TIM-3 antibody in the preparation of drugs for treating TIM-3-related conditions.

Abstract: Provided are a human GCGR antibody, a GLP-1 peptid and a mutant thereof, as well as a bispecific protein formed by fusion of the GCGR antibody and the GLP-1 peptide and a preparation method thereof, which can be used for weight loss and diabetes treatment.

Abstract: Disclosed is use of a TIM-3 antibody in preparation of medicines for treating tumors. Specifically, provided is use of the TIM-3 antibody or an antigen-binding fragment thereof in preparation of medicines for treating non-small cell lung cancer, the TIM-3 antibody containing a heavy chain variable region shown in SEQ ID NO: 33 and a light chain variable region shown in SEQ ID NO: 36. Further, also provided is use of the TIM-3 antibody or the antigen-binding fragment thereof and a PD-1 antibody or an antigen-binding fragment thereof in joint preparation of medicines for treating tumors.

Abstract: Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.

Abstract: Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.

Abstract: Disclosed in the present application are a TIM3 antibody pharmaceutical composition and use thereof. In particular, the pharmaceutical composition comprises a TIM3 antibody or antigen-binding fragment thereof in a buffer. In addition, the pharmaceutical composition further comprises a saccharide and a nonionic surfactant. The pharmaceutical composition of the present invention has good stability.

Abstract: Provided are a CD96 antibody, an antigen-binding fragment and a pharmaceutical use thereof. Further provided are a murine antibody, a chimeric antibody and a humanized antibody comprising the CDR region of the CD96 antibody, and a pharmaceutical composition comprising the CD96 antibody and the antigen-binding fragment thereof, and the use of same as a drug. In particular, provided is a use of a humanized CD96 antibody in the preparation of a drug for treating CD96-related diseases or conditions.

Abstract: A TIGIT antibody, an antigen-binding fragment thereof, and a medical use thereof. The present invention relates to a murine antibody, a chimeric antibody, and a humanized antibody comprising a CDR region of the TIGIT antibody, and a pharmaceutical composition comprising the TIGIT antibody and the antigen-binding fragment thereof, and a use thereof as a medicament. In particular, the present invention also relates to a use of a humanized TIGIT antibody for preparing a medicament for the treatment of TIGIT-associated diseases or conditions.